18F-DCFPyL PET/CT in Men with Prostate Cancer

Protocol: 
AAAS1862
Phase: 
II/III

18F-DCFPyL PET/CT in Men with Prostate Cancer

The purpose of this study is to see if [18F]DCFPyL (PyL) PET/CT scans are able
to find prostate cancer tumors. PyL is a radioactive drug (tracer) that targets
prostate specific membrane antigen (PSMA). Because PSMA is a protein found
mostly on the surface of prostate cancer cells, we are testing to see if PyL
will be able to correctly identify prostate cancer. We will also see if we can
detect prostate cancer tumor DNA (ctDNA) and cell particles (exosomes) in the
blood. We hope that this may one day lead to better tests to evaluate patients
with prostate cancer.

Are you Eligible? (Inclusion Criteria)

Are you a man of at least 18 years of age?
Do you have confirmed prostate cancer?
Are you able to perform everyday tasks independently?

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States